Mephedrone half-life
Controlled intranasal administration produced mean half-lives near two hours in both plasma and whole blood.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. The shaded band shows the reported half-life range. This is a mathematical visualization, not a personal concentration estimate.
Mephedrone: evidence and interpretation notes
What the curve is actually following
Controlled intranasal administration produced mean half-lives near two hours in both plasma and whole blood. The profile uses that route- and matrix-specific result rather than the earlier generic 2.5-hour placeholder.
For the interactive chart, HalfLifeDB starts with 2.05 hours as the representative value for Mephedrone after controlled intranasal administration. Route, formulation, sampling, and metabolites remain attached to that label instead of being hidden inside the arithmetic.
Mephedrone has controlled human pharmacokinetic literature, including studies that measure metabolites and different sampling matrices.
The 2.5 hour value gives a short stimulant-like curve. Route, enantiomers, metabolites, and matrix choice can change how published data should be read.
The citations include LC-MS/MS human pharmacokinetic work, controlled intranasal administration research, and the compound record.
This page does not describe use patterns, toxicity management, or behavioral effects.
For Mephedrone, persistence in the model should be separated from alertness, euphoria, appetite change, sleep disruption, and cardiovascular effects. Those outcomes can diverge from parent-drug decline.
What each source contributes
- Meyer MR et al. Pharmacokinetics of mephedrone and metabolites in human by LC-MS/MS (2017). This metabolism study identifies pathways, metabolites, or analytical targets and does not by itself create a complete human concentration-time curve.
- Papaseit E et al. Pharmacokinetics of mephedrone after controlled intranasal administration (2021). This human pharmacokinetic record adds measured route, analyte, and population context and does not become a universal result.
- PubChem: Mephedrone. This identity record confirms names and compound identity and does not supply a human half-life.
For Mephedrone, the numerical model is tied most closely to Meyer MR et al. Pharmacokinetics of mephedrone and metabolites in human by LC-MS/MS (2017). As a metabolism study, it identifies pathways, metabolites, or analytical targets; it does not by itself create a complete human concentration-time curve.
Why the range stays visible
The 1.98-to-2.12-hour range is retained beside the 2.05-hour input for Mephedrone after controlled intranasal administration. It is not an uncertainty slider or a personalized prediction; it shows that the cited literature does not reduce to one invariant value.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 2.0 h as a representative input for Mephedrone after controlled intranasal administration. In the simplified model, about 0.0% remains after 24 hours and about 3% remains after five half-lives, or roughly 10.3 h.
This is a short curve. The modeled amount changes noticeably over the same day, while effects, metabolites, and safety questions can still follow a different timeline. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
stimulant context
Stimulant half-life estimates can shift with urine pH, enzyme activity, formulation, dose, and whether metabolites are measured separately.
- Alertness or subjective stimulation can end before modeled elimination.
- Sleep disruption and downstream effects are not represented by the curve.
- Formulation and route can change peak timing without changing the displayed model.
ComparisonTimeline checkpoints and nearby profiles
Mephedrone timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 6 h | 13.2% | Long-tail portion of the model |
| 12 h | 1.73% | Low modeled remainder, not a clearance guarantee |
| 24 h | 0.03% | Low modeled remainder, not a clearance guarantee |
| 2.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
| 3.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Mephedrone within the stimulant group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
- Methylphenidate (3 h)
- Nicotine (2 h)
- Caffeine (5 h)
- Cocaine (1 h)
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 2.0 h |
|---|---|
| Modeled analyte or phase | Mephedrone after controlled intranasal administration |
| Reported range | 2.0 h to 2.1 h |
| Curve type | Normalized, first-order decline |
Selection note: Controlled intranasal administration produced mean half-lives near two hours in both plasma and whole blood. The profile uses that route- and matrix-specific result rather than the earlier generic 2.5-hour placeholder.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Research abstract Meyer MR et al. Pharmacokinetics of mephedrone and metabolites in human by LC-MS/MS (2017).Metabolism-focused evidence used to identify pathways or analytes. It does not automatically establish a population half-life.
- Research abstract Papaseit E et al. Pharmacokinetics of mephedrone after controlled intranasal administration (2021).Direct pharmacokinetic context. Population, route, formulation, analyte, and sampling duration still determine how broadly the result can be applied.
- Identity record PubChem Compound Summary: Mephedrone.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the stimulant group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.